Abstract
Background: Infectious diseases still affect large populations causing significant morbidity and mortality. Bacterial and fungal infections for centuries were the main factors of death and disability of millions of humans. Despite the progress in the control of infectious diseases, the appearance of resistance of microbes to existing drugs creates the need for the development of new effective antimicrobial agents. In an attempt to improve the antibacterial activity of previously synthesized compounds modifications to their structures were performed. Methods: Nineteen thiazolidinone derivatives with 6-Cl, 4-OMe, 6-CN, 6-adamantan, 4-Me, 6-adamantan substituents at benzothiazole ring were synthesized and evaluated against panel of four bacterial strains
S. aureus
,
L. monocytogenes
,
E. coli
and
S. typhimirium
and three resistant strains MRSA,
E. coli
and
P. aeruginosa
in order to improve activity of previously evaluated 6-OCF
3
-benzothiazole-based thiazolidinones. The evaluation of minimum inhibitory and minimum bactericidal concentration was determined by microdilution method. As reference compounds ampicillin and streptomycin were used. Results: All compounds showed antibacterial activity with MIC in range of 0.12–0.75 mg/mL and MBC at 0.25–>1.00 mg/mL The most active compound among all tested appeared to be compound
18,
with MIC at 0.10 mg/mL and MBC at 0.12 mg/mL against
P. aeruginosa.
as well as against resistant strain
P. aeruginosa
with MIC at 0.06 mg/mL and MBC at 0.12 mg/mL almost equipotent with streptomycin and better than ampicillin. Docking studies predicted that the inhibition of LD-carboxypeptidase is probably the possible mechanism of antibacterial activity of tested compounds. Conclusion: The best improvement of antibacterial activity after modifications was achieved by replacement of 6-OCF
3
substituent in benzothiazole moiety by 6-Cl against
S. aureus
,
MRSA
and resistant strain of
E. coli
by 2.5 folds, while against
L. monocytogenes
and
S. typhimirium
from 4 to 5 folds.